本期内容提示:
1、$Sierra Oncology(SRRA)、$安塔尔制药(ATRS)等多家药企被收购,医药板块是否会迎来反转契机?
2、今年商业化阶段的创新药药企受青睐,哪些公司值得配置?
3、$Protagonist(PTGX)暴跌,是否有抄底机会?
$百济神州-U(SH68823...查看全文
等等达文西2021-03-09 00:17
$安塔尔制药(ATRS)$ 5块是很强的阻力位,破了五块,应该能翻倍。 再观察观察,我可能会在4块附件捡一些仓位,毕竟这个货的业绩转强很多,希望能破五块。查看全文
5月11日,资本邦了解到,美股上市公司安塔尔制药(ATRS.US)发布2022财年一季报。 2022年1月1日-2022年3月31日,公司营业收入4155.70万美元,同比下降1.25%,归属母公司净亏损232.10万美元,同比止盈转亏,去年同期净利379.30万美元,基本每股收益为-0... 网页链接
$安塔尔制药(ATRS)$ SC 14D9/A [Amend] Solicitation, recommendation statements Accession Number: 0001140361-22-019107 Act: 34 Size: 46 KB 网页链接
$安塔尔制药(ATRS)$ SC 14D9/A [Amend] Solicitation, recommendation statements Accession Number: 0001140361-22-018759 Act: 34 Size: 25 KB 网页链接
$安塔尔制药(ATRS)$ SC TO-T/A [Amend] Tender offer statement by Third Party Accession Number: 0001193125-22-148040 Act: 34 Size: 59 KB 网页链接
$安塔尔制药(ATRS)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001016169-22-000044 Act: 34 Size: 5 MB 网页链接
$安塔尔制药(ATRS)$ SC 14D9/A [Amend] Solicitation, recommendation statements Accession Number: 0001140361-22-018496 Act: 34 Size: 21 KB 网页链接
$安塔尔制药(ATRS)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001172661-22-001185 Act: 34 Size: 55 KB 网页链接
$安塔尔制药(ATRS)$ SC TO-T/A [Amend] Tender offer statement by Third Party Accession Number: 0001193125-22-136980 Act: 34 Size: 215 KB 网页链接
$安塔尔制药(ATRS)$ SC 14D9/A [Amend] Solicitation, recommendation statements Accession Number: 0001140361-22-017289 Act: 34 Size: 25 KB 网页链接
$安塔尔制药(ATRS)$ SC 13D General statement of acquisition of beneficial ownership Accession Number: 0001104659-22-053860 Act: 34 Size: 132 KB 网页链接
$安塔尔制药(ATRS)$ 10-K/A [Amend] Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001140361-22-017040 Act: 34 Size: 1 MB 网页链接